CCL2 rs1024611Gene Polymorphism in Philadelphia-Negative Myeloproliferative Neoplasms

Hodeib, Hossam; Abd EL Hai, Dina; Tawfik, Mohamed A; Allam, Alzahraa A.; Selim, Amal; Elsawy, Abdallah Ahmed; Youssef, Amira

doi:10.3390/genes13030492

Open AccessArticle

CCL2 rs1024611Gene Polymorphism in Philadelphia-Negative Myeloproliferative Neoplasms

by

Hossam Hodeib

¹,

Dina Abd EL Hai

¹,

Mohamed A Tawfik

^2,*

,

Alzahraa A. Allam

²,

Amal Selim

²,

Abdallah Ahmed Elsawy

² and

Amira Youssef

¹

Clinical Pathology Department, Faculty of Medicine, Tanta University, Tanta 31527, Egypt

²

Internal Medicine Department, Faculty of Medicine, Tanta University, Tanta 31527, Egypt

^*

Author to whom correspondence should be addressed.

Genes 2022, 13(3), 492; https://doi.org/10.3390/genes13030492

Submission received: 21 January 2022 / Revised: 20 February 2022 / Accepted: 8 March 2022 / Published: 10 March 2022

(This article belongs to the Section Human Genomics and Genetic Diseases)

Download

Browse Figures

Versions Notes

Abstract

Introduction: The onset of the Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs) is caused by acquired somatic mutations in target myeloid genes “driver mutations”. The CCL2 gene is overexpressed by non-Hodgkin lymphomas and multiple solid tumors. Aim of the study: to evaluate the possible association of CCL2 rs1024611 SNP and its expression level and the risk of developing Philadelphia-negative MPNs. Patients and methods: A total of 128 newly diagnosed Philadelphia-negative MPN patient and 141 healthy subjects were evaluated for the genotype distribution of CCL2 rs1024611 and CCL2 expression levels. Results: The CCL2 rs1024611 G/G genotype was more frequent and significantly frequent among PMF and Post-PV/ET-MF patients and the mean CCL2 expression levels were significantly higher in PMF and Post-PV/ET-MF compared to the healthy subjects. The CCL2 rs1024611 SNP was significantly correlated to the CCL2 gene expression level and fibrosis grade. ROC analysis for the CCL2 gene expression level that discriminates MF patients from PV + ET patients revealed a sensitivity of 80.43% and a specificity of 73.17% with an AUC of 0.919 (p < 0.001). Conclusion: The CCL2 rs1024611 polymorphism could be an independent risk factor for developing MF (PMF and Post-PV/ET-MF). Moreover, CCL2 gene expression could be potential genetic biomarker of fibrotic progression.

Keywords: Philadelphia; myeloproliferative; polymorphism; CCL2 rs1024611Gene

Share and Cite

MDPI and ACS Style

Hodeib, H.; Abd EL Hai, D.; Tawfik, M.A.; Allam, A.A.; Selim, A.; Elsawy, A.A.; Youssef, A. CCL2 rs1024611Gene Polymorphism in Philadelphia-Negative Myeloproliferative Neoplasms. Genes 2022, 13, 492. https://doi.org/10.3390/genes13030492

AMA Style

Hodeib H, Abd EL Hai D, Tawfik MA, Allam AA, Selim A, Elsawy AA, Youssef A. CCL2 rs1024611Gene Polymorphism in Philadelphia-Negative Myeloproliferative Neoplasms. Genes. 2022; 13(3):492. https://doi.org/10.3390/genes13030492

Chicago/Turabian Style

Hodeib, Hossam, Dina Abd EL Hai, Mohamed A Tawfik, Alzahraa A. Allam, Amal Selim, Abdallah Ahmed Elsawy, and Amira Youssef. 2022. "CCL2 rs1024611Gene Polymorphism in Philadelphia-Negative Myeloproliferative Neoplasms" Genes 13, no. 3: 492. https://doi.org/10.3390/genes13030492

APA Style

Hodeib, H., Abd EL Hai, D., Tawfik, M. A., Allam, A. A., Selim, A., Elsawy, A. A., & Youssef, A. (2022). CCL2 rs1024611Gene Polymorphism in Philadelphia-Negative Myeloproliferative Neoplasms. Genes, 13(3), 492. https://doi.org/10.3390/genes13030492

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Menu

CCL2 rs1024611Gene Polymorphism in Philadelphia-Negative Myeloproliferative Neoplasms

Abstract

Share and Cite

Article Metrics

Article Access Statistics

Further Information

Guidelines

MDPI Initiatives

Follow MDPI